| Keywords: |
gene mutation; gene sequence; single nucleotide polymorphism; genetics; missense mutation; cancer risk; united states; rad50 protein; rad50 gene; genetic predisposition to disease; breast cancer; genetic association; genetic variability; genetic variation; practice guideline; mutational analysis; breast neoplasms; heterozygote; protein p53; uvomorulin; risk assessment; risk; tumor suppressor gene; genes, brca1; genes, brca2; public health service; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; atm protein; dna sequence; checkpoint kinase 2; genetic risk; genetic predisposition; genetic screening; protein mlh1; protein msh2; protein msh6; mismatch repair protein pms2; mlh1 gene; genetic testing; standards; guidelines as topic; sequence analysis, dna; pten gene; centers for disease control and prevention (u.s.); atm gene; fanconi anemia group c protein; dna glycosylase muty; protein kinase lkb1; chek2 gene; tp53 gene; msh2 gene; nf1 gene; cancer prognosis; msh6 gene; brip1 gene; fancc gene; palb2 gene; rad51c gene; genotyping techniques; genotyping technique; humans; human; female; priority journal; article; mutyh gene; pms2 gene; men1 gene; cdh1 gene; fancm gene; mre11a gene; nbn gene; ppm1d gene; rad51d gene; stk11 gene; xrcc2 gene
|
